ClinicalTrials.gg
CompletedNCT02831361Updated Feb 22, 2018

Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)

A Phase 3 interventional study of Gemigliptin and Gemigliptin placebo in Type 2 Diabetes Mellitus, sponsored by LG Life Sciences. Completed. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2018-02-22.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
290
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. gemigliptin · Diabetes Mellitus, Type 2.

Enrollment
5th of 18
290 · median 130
Started
2016
with 1 other
Phase 3
9 of 18
none open now
Registered
10th of 18
by date
Lead sponsor
8 of 18
LG Life Sciences

Among the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 9 in phase 3, and was the 10th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About gemigliptin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing gemigliptin in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control on insulin alone or on insulin in combination with metformin stably for 8 weeks.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with type 2 diabetes mellitus of ≥19 years of age at the time of Visit 1 (Screening)
  2. Patients with and FPG values measured at central laboratory satisfying the following conditions at the time of Visit 1(Screening)

    • Patients who had not taken OADs other than metformin within 8 weeks prior to Visit 1(Screening) : 7.0% ≤ HbA1c ≤ 11%, FPG \< 270mg/dl
    • Patients who had taken OADs other than metformin within 8 weeks prior to Visit 1(Screening) : 6.5% ≤ HbA1c ≤ 10.5%, FPG \< 270mg/dl However, re-test can be carried out only once during the visit window, if the central laboratory values don't meet the criteria mentioned above.
  3. Patients who had stably received minimum ≥15 U/day and maximum ≤1 U/kg/day of insulin(long-acting, intermediate-acting or pre-mixed) for 8 weeks prior to Visit 1(Screening) ( 'Stably' is defined as the cases in which mean total daily dose of insulin is adjusted to range between ±10% of the dose used on the day of Visit 1(Screening) for 8 weeks prior to Visit 1(Screening).
  4. For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily without dose adjustment for 8 weeks prior to Visit 1(Screening)
  5. Patients who are applicable to one of the three in the following.

    1. Surgically infertile patients
    2. female patients of ≥45 years of age for whom ≥2 years elapsed since their last menstruation
    3. Premenopausal fertile female patients or surgically non-infertile male patients who have agreed to use at least 2 kinds of measures (certainly including one of the barrier methods) to avoid pregnancy until 14 days after the last dose of the product

      • Barrier methods: Condom, Diaphragm, Cervical cap(Pessary), Spermicide
      • Hormonal methods: Pills, Injection(Depot), Skin patch, Hormonal implant(Implanon), Vaginal ring
      • Intrauterine Devices(IUDs): Cooper IUD(Loop), Hormonal IUD(Mirena)
      • Natural methods: Basic body temperature, Ovulation period, Coitus interruptus, Abstinence
  6. Patients who have signed an themselves after receiving explanation about the objectives, methods, effects, etc. of the clinical study

    For patients who have gone through the , the inclusion criteria below should be checked at Visit 1-1(Screening).

  7. Patients whose HbA1c and FPG measured at Visit 1-1(Screening) are 7.0%\~11% and \<270 mg/dl, respectively
  8. Patients whose mean daily dose of insulin checked at Visit 1-1(Screening) ranges between ±10% of the dose checked at Visit 1(Screening)

Exclusion criteria

Exclusion Criteria:

  1. Patients with type 1 diabetes mellitus*, gestational diabetes, or secondary diabetes
  2. Patients with (BMI) >40 kg/m2 at the time of Visit 1(Screening)
  3. Patients with a history of the following

    • Patients who had experienced severe hypoglycaemia within 24 weeks prior to Visit 1(Screening) or who had experienced hypoglycaemia at least 3 times a week within 8 weeks prior to Visit 1(Screening)†
    • Patients with a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma within 24 weeks prior to Visit 1(Screening) #
    • Patients with a history of myocardial infarction, unstable angina, and coronary artery bypass graft(CABG) within 24 weeks prior to Visit 1(Screening)
    • Patients with Class III, IV congestive heart failure or arrhythmia requiring treatment at the time of Visit 1(Screening)
    • Patients whose TSH level is out of the normal range and who have thyroidal dysfunction requiring drug therapy at the time of Visit 1(Screening) (However, those who have been taking thyroid hormone at a fixed dose since previous 4 weeks prior to Visit 1[Screening] and whose TSH level is within the normal range can participate in the study.)
    • Patients with severe infection or severe trauma at the time of Visit 1(Screening)
    • Patients who had had a surgical operation within 4 weeks prior to Visit 1(Screening) (excluding minor surgeries without restriction on food and fluid intake) or who are scheduled to have a significant surgery during the study period
    • Patients with pituitary insufficiency or adrenal insufficiency at the time of Visit 1(Screening)
    • Patients with pulmonary embolism, severe pulmonary dysfunction, or who are susceptible to be accompanied by hypoxemia at the time of Visit 1(Screening)
    • Patients on drug therapy due to gastrointestinal disturbance including dehydration, diarrhea, and vomiting at the time of Visit 1(Screening)#
    • Patients who are positive carriers for virus(HBV), virus(HCV), or (HIV) at the time of Visit 1(Screening) visit
    • Patients with a history of alcoholism or drug addiction within 1 year prior to Visit 1(Screening)
    • Patients with a history of malignant tumors within 5 years prior to Visit 1(Screening). However, patients with basal cell or squamous cell skin cancer, or in situ cervical cancer treated properly can participate in the study.
    • Patients with end-stage renal disease(ESRD) at the time of Visit 1(Screening)
  4. Patients with the outcomes of the laboratory tests performed at Visit 1(Screening) applicable to the criteria below

    • >1.5 × (ULN)
    • /ALT >2.5 × ULN
  5. Male and female patients on metformin and with serum creatinine level of ≥1.5 mg/dl and ≥1.4 mg/dl, respectively at the time of Visit 1(Screening)
  6. Patients with a history of reactions to the drugs below

    • Gemigliptin or drugs belonging to dipeptidyl-peptidase4(DPP4) inhibitors
    • Metformin or drugs belonging to biguanides
    • Insulin
  7. Patients who were administered the drugs below

    • Patients who had been administered anti-obesity drugs within 12 weeks prior to Visit 1(Screening)
    • Patients who had been administered short-acting or rapid-acting insulin before meals within 8 weeks prior to Visit 1(Screening)
    • Patients who had been administered GLP-1 analogues within 8 weeks prior to Visit 1(Screening)
    • Patients who had been administered warfarin, dicoumarin, and digoxin within 4 weeks prior to Visit 1(Screening)
    • Patients who had been being administered continuously within 2 weeks prior to Visit 1(Screening) or who are required to take glucocorticoids continuously in the future
    • Patients who are being administered any of the strong inducers (rifampicin[rifampin], dexamethasone, phenytoin, carbamazepine, rifabutin, phenobarbital) at the time of Visit 1(Screening)*
    • Patients who are being administered cimetidine at the time of Visit 1(Screening)
  8. Female patients who are pregnant or lactating
  9. Patients who have an experience of participation in another clinical study within 12 weeks prior to Visit1(screening)
  10. Patients who are otherwise considered to be ineligible for this study on investigators' judgment For patients who have gone through the , the exclusion criteria below should be checked at Visit 1-1(Screening).
  11. Patients whose mean daily dose of insulin during the 8-week washout period which has been beyond ±10% of the dose checked at Visit 1(Screening) for ≥ 12 days or for 5 consecutive days

At Visit 1(Screening) or Visit 1-1(Screening), subjects who meet the inclusion/exclusion criteria can enter the 2-week run-in period along with exercise/diet.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
290 participants (actual)

Study arms

  • Experimental
    Gemigliptin 50mg

    the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total

    Drug: Gemigliptin · Drug: Metformin · Procedure: Diet/exercise questionnaire

  • Placebo comparator
    Gemigliptin 50mg placebo

    the subjects should visit a study site at an interval of 6 weeks during the treatment period for 24 weeks in total

    Drug: Gemigliptin placebo · Drug: Metformin · Procedure: Diet/exercise questionnaire

Interventions

  • DrugGemigliptin placebo
  • For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study

  • ProcedureDiet/exercise questionnaire

    doing exercise with about intermediate intensity(50\~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period. the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25

06

What researchers measure

Primary outcomes

  1. changes from baseline HbA1c at week 25

    Time frame: baseline (Visit 2) and week 25 (visit 6)

Secondary outcomes

  1. Responder Rate at week 25

    HbA1c \<7% , HbA1c \<6.5%

    Time frame: week 25 (visit 6)

  2. Changes of HbA1c at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: baseline(visit 2), week 7(visit 3), week 13(visit 4), week 19(visit 5), week 25(visit 6)

  3. Changes of FPG at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: baseline(visit 2), week 7(visit 3), week 13(visit 4), week 19(visit 5), week 25(visit 6)

  4. Changes of Fasting serum C-peptide at week 25

    Time frame: baseline (Visit 2) and week 25 (visit 6)

  5. Changes of HOMA-IR at week 25

    Time frame: baseline (Visit 2) and week 25 (visit 6)

  6. Changes of HOMA-β at week 25

    Time frame: baseline (Visit 2) and week 25 (visit 6)

Other outcomes

  1. Changes of Total Cholesterol at week 25

    Time frame: baseline (Visit 2) and week 25 (visit 6)

  2. Changes of cardiovascular disease parameter at week 25

    hsCRP

    Time frame: baseline (Visit 2) and week 25 (visit 6)

  3. Changes of body weight at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: baseline(visit 2), week 7(visit 3), week 13(visit 4), week 19(visit 5), week 25(visit 6)

  4. Changes of waist circumference at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: baseline(visit 2), week 7(visit 3), week 13(visit 4), week 19(visit 5), week 25(visit 6)

  5. Changes of total daily dose at each visit

    values of parameters at the corresponding visit - values of parameters at visit 2(baseline)

    Time frame: visit 2, visit 3, visit 4, visit 5, visit 6

  6. Changes of LDL-C at week 25

    Time frame: baseline (Visit 2) and week 25 (visit 6)

  7. Changes of HDL-C at week 25

    Time frame: baseline (Visit 2) and week 25 (visit 6)

  8. Changes of Triglyceride at week 25

    Time frame: baseline (Visit 2) and week 25 (visit 6)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Feb 2018, 15 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 15 months is below that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2016
First posted
Jul 13, 2016
StartActual
Oct 17, 2016
Primary completionActual
Feb 8, 2018
CompletionActual
Feb 8, 2018
Last update
Feb 22, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02831361
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Jul 13, 2016
Start date
Oct 17, 2016
Primary completion
Feb 8, 2018
Completion
Feb 8, 2018
Last update
Feb 22, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemigliptin

Start the discussion